Prišlo je do najnovejšega odkritja pri nedrobnoceličnem pljučnem raku. Vrsta imunizacija ki lahko zdravi nedrobnocelični pljučni rak (NSCLC), je doživel 3. stopnjo klinične odobritve in ima velik terapevtski vpliv na nedrobnocelično pljučno bolezen. Zdaj je na voljo v zelo malo državah.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung cepivo proti raku lahko izboljša stopnjo preživetja bolnikov z relapsom in napredovalim (stadij IIIB/IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Ko nevsiljivi okvir tvori eksplicitna protitelesa proti antigenlahko ustvari protitelesa proti edinstvenosti glavnega antigena, ki lahko nadzoruje odporni okvir od znotraj. Po imunizaciji proti tej pljučni maligni rasti imunizacija, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumor antigeni.
Klinično je bilo dokazano, da pljučna bolezen imunizacija je zelo trpel in ima boljše počutje. Številni osnovni simptomi se pojavijo le lokalno (mesto infundiranja) in so na splošno nežni in kratkotrajni. Ne glede na to, ali se protitelo daje bolnikom po razpadu njihovega stanja, se je njihova splošna vzdržljivost izboljšala.
Trenutno tovrstne imunizacije pljučne rasti v Indiji ne spodbujajo.
